CN118477076A - 用于治疗pik3ca相关过度生长综合征群的方法 - Google Patents

用于治疗pik3ca相关过度生长综合征群的方法 Download PDF

Info

Publication number
CN118477076A
CN118477076A CN202410563611.0A CN202410563611A CN118477076A CN 118477076 A CN118477076 A CN 118477076A CN 202410563611 A CN202410563611 A CN 202410563611A CN 118477076 A CN118477076 A CN 118477076A
Authority
CN
China
Prior art keywords
byl719
pros
pik3ca
syndrome
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410563611.0A
Other languages
English (en)
Chinese (zh)
Inventor
G·卡诺德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Western Dais Paris, University of
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Western Dais Paris, University of
Centre National de la Recherche Scientifique CNRS
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Western Dais Paris, University of, Centre National de la Recherche Scientifique CNRS, Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Western Dais Paris, University of
Publication of CN118477076A publication Critical patent/CN118477076A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Spectrometry And Color Measurement (AREA)
CN202410563611.0A 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法 Pending CN118477076A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16305193.1 2016-02-19
EP16305193 2016-02-19
PCT/EP2017/053587 WO2017140828A1 (en) 2016-02-19 2017-02-17 Byl719 (alpelisib) for use in the treatment of pik3ca-related overgrowth spectrum (pros - cloves syndrome)
CN201780011659.9A CN109562103A (zh) 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780011659.9A Division CN109562103A (zh) 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法

Publications (1)

Publication Number Publication Date
CN118477076A true CN118477076A (zh) 2024-08-13

Family

ID=55409795

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202410562274.3A Pending CN118477075A (zh) 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法
CN201780011659.9A Pending CN109562103A (zh) 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法
CN202410563611.0A Pending CN118477076A (zh) 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202410562274.3A Pending CN118477075A (zh) 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法
CN201780011659.9A Pending CN109562103A (zh) 2016-02-19 2017-02-17 用于治疗pik3ca相关过度生长综合征群的方法

Country Status (8)

Country Link
US (4) US11433059B2 (enExample)
EP (1) EP3416642A1 (enExample)
JP (3) JP7051693B2 (enExample)
KR (1) KR20180115297A (enExample)
CN (3) CN118477075A (enExample)
AU (3) AU2017219834B2 (enExample)
CA (1) CA3013845C (enExample)
WO (1) WO2017140828A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2985894A1 (en) 2015-05-15 2016-11-24 Memorial Sloan-Kettering Cancer Center Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations
KR20180115297A (ko) 2016-02-19 2018-10-22 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Pik3ca-관련된 과성장 스펙트럼(pros-cloves 증후군)의 치료시 사용하기 위한 byl719(알펠리시브)
MX2021009142A (es) 2019-02-06 2021-10-13 Venthera Inc Inhibidores topicos de fosfoinositol 3-cinasas.
WO2025045915A1 (en) * 2023-08-29 2025-03-06 Institut National de la Santé et de la Recherche Médicale Methods for inducing muscle hypertrophy
WO2025045129A1 (zh) * 2023-08-30 2025-03-06 广州嘉越医药科技有限公司 化合物用于治疗pros谱系疾病的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101583357B (zh) * 2006-08-29 2013-03-20 新加坡国立癌症中心 Mtor拮抗剂和血管生成抑制剂用于制备治疗癌症的药物的用途
AR082418A1 (es) * 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
EP2976106B1 (en) * 2013-03-21 2021-04-14 Array BioPharma Inc. Combination therapy comprising a b-raf inhibitor and a second inhibitor
CA2985894A1 (en) * 2015-05-15 2016-11-24 Memorial Sloan-Kettering Cancer Center Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations
KR20180115297A (ko) 2016-02-19 2018-10-22 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Pik3ca-관련된 과성장 스펙트럼(pros-cloves 증후군)의 치료시 사용하기 위한 byl719(알펠리시브)

Also Published As

Publication number Publication date
CA3013845C (en) 2024-09-17
US20250339417A1 (en) 2025-11-06
AU2017219834A1 (en) 2018-08-23
CN118477075A (zh) 2024-08-13
JP2019505549A (ja) 2019-02-28
CA3013845A1 (en) 2017-08-24
WO2017140828A1 (en) 2017-08-24
US12427141B2 (en) 2025-09-30
JP2022058800A (ja) 2022-04-12
AU2022235569B2 (en) 2024-10-10
US11433059B2 (en) 2022-09-06
AU2024278598A1 (en) 2025-01-16
EP3416642A1 (en) 2018-12-26
CN109562103A (zh) 2019-04-02
US20220323428A1 (en) 2022-10-13
US20250295645A1 (en) 2025-09-25
AU2022235569A1 (en) 2022-10-13
AU2017219834B2 (en) 2022-06-30
JP2024125429A (ja) 2024-09-18
JP7051693B2 (ja) 2022-04-11
US20200215044A1 (en) 2020-07-09
KR20180115297A (ko) 2018-10-22

Similar Documents

Publication Publication Date Title
US12427141B2 (en) BYL719 (alpelisib) for use in the treatment of PIK3CA-related overgrowth spectrum (PROS-CLOVES syndrome)
EP2959894B1 (en) S1p receptor modulators for treating multiple sclerosis
US11723911B2 (en) Treatment of demyelinating diseases
KR20200098536A (ko) Dux4 발현과 관련된 질병의 치료를 위한 화합물
EP3294314A1 (en) Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations
JP4499560B2 (ja) Ｉｉ型糖尿病を治療又は予防するためのインターロイキン１受容体アンタゴニスト及び／又はピロリジンジチオカルバメートの使用
KR102174191B1 (ko) 조직 재생 및 저하된 조직 기능의 회복을 자극하기 위한 제제로서의 디카르복시산의 비스아미드 유도체
Hayes et al. Preserved Left Ventricular Function despite Myocardial Fibrosis and Myopathy in the Dystrophin‐Deficient D2. B10‐Dmdmdx/J Mouse
CN110511266B (zh) 一种小分子多肽及其用途
EP3747468A1 (en) Therapeutic agent for frontotemporal lobar degeneration, method for screening therapeutic agent for frontotemporal lobar degeneration and method for treating frontotemporal lobar degeneration
JP7168228B2 (ja) 脳神経疾患に対するペプチドワクチン及びペプチドワクチン組成物
JP2007511522A (ja) 血管新生およびがん細胞増殖の調節方法
Górska Diffuse alveolar hemorrhage in a chronically hemodialyzed patient with progressive necrotic skin lesions as a manifestation of calciphylaxis
WO2018027149A1 (en) Methods of treating alport syndrome
TW202519221A (zh) Ｗｅｅ１抑制劑及ｐｋｍｙｔ１抑制劑之組合
JP2024020797A (ja) 筋萎縮の治療剤
WO2025125788A1 (en) Sabizabulin for use in the treatment of polycystic kidney disease
WO2024128311A1 (ja) 脈管奇形用医薬組成物及び脈管奇形の治療方法
HK1214758B (en) S1p receptor modulators for treating multiple sclerosis
EP2687264A1 (en) Macrophage Activating Factor for treatment of endometriosis
WO2012011572A1 (ja) 拡張不全型心不全治療薬

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination